Verification (slot-7, 2026-03-17 22:58 PT): AD/PD pipeline index pages verified. AD Pipeline (ID 12958, 5K chars) and PD Pipeline (ID 12959, 5.2K chars) both have substantial content with company listings, pipeline details, and cross-links to disease pages. Company pages (199 total) include pipeline drugs, funding info, trial results. All infrastructure in excellent shape.
This page provides an index of biotechnology and pharmaceutical companies actively developing treatments for Alzheimer's disease (AD).
The AD drug development landscape includes major pharmaceutical companies with late-stage programs and innovative biotechnology companies with novel mechanisms of action. Key therapeutic approaches include:
- Amyloid-targeting therapies: Monoclonal antibodies, vaccines
- Tau](/proteins/tau)-targeting therapies: Anti-tau antibodies, ASO, aggregation inhibitors
- Neuroprotective agents: Sigma-1 agonists, GLP-1 agonists
- Anti-inflammatory approaches: Microglial modulators
| Company |
Key Drugs |
Phase |
| Biogen Inc. |
Leqembi (approved), Remternetug (Phase 3) |
Approved/Phase 3 |
| Eli Lilly and Company |
Donanemab (approved), Remimseren (Phase 2) |
Approved/Phase 2 |
| Eisai Co., Ltd. |
Leqembi (approved), E2814 (Phase 1/2) |
Approved/Phase 2 |
| Roche |
Crenezumab (discontinued), other programs |
Various |
| Company |
Key Drug |
Mechanism |
Phase |
| Denali Therapeutics Inc. |
DNL919 |
TREM2](/proteins/trem2) agonist |
Preclinical |
| AC Immune SA |
ACI-35.030 |
Tau vaccine |
Phase 2 |
| Prothena Corporation |
PRX012 |
Anti-Aβ mAb |
Phase 1 |
| Annovis Bio, Inc. |
Bunodimod |
Sigma-1 agonist |
Phase 2/3 |
| Company |
Focus Area |
| Vaxxinity |
Therapeutic vaccines |
| INmune Bio |
Neuroinflammation |
| Acumen Pharmaceuticals |
TREM2 antibodies |
| Pinteon Therapeutics |
Tau immunotherapy |
| Gain Therapeutics |
Protein stabilization |
| Company |
Drug |
Target |
Phase |
| Biogen/Eisai |
Lecanemab |
Aβ protofibrils |
Approved |
| Eli Lilly |
Donanemab |
Aβ plaques |
Approved |
| Biogen |
Remternetug |
Aβ |
Phase 3 |
| Prothena |
PRX012 |
Aβ |
Phase 1 |
| Company |
Drug |
Target |
Phase |
| Biogen |
BIIB080 (IONIS-MAPTRx) |
Tau ASO |
Phase 1b/2a |
| Eisai |
E2814 |
Tau mAb |
Phase 1/2 |
| AC Immune |
ACI-35.030 |
pTau vaccine |
Phase 2 |
| Eli Lilly |
LY3884969 |
Tau mAb |
Phase 1 |
| Company |
Drug |
Mechanism |
Phase |
| Eli Lilly |
Remimseren |
GLP-1/GIP agonist |
Phase 2 |
| Annovis Bio |
Bunodimod |
Sigma-1 agonist |
Phase 2/3 |
| Phase |
Number of AD Trials |
| Phase 1 |
~80 |
| Phase 2 |
~150 |
| Phase 3 |
~50 |
- Early intervention: Most successful trials target early AD (MCI due to AD, mild dementia)
- Biomarker confirmation: Amyloid PET positivity required in most trials
- Efficacy endpoints: Clinical cognition measures (ADAS-Cog, CDR-SB) paired with biomarkers
graph TD
Biogen --- Eisai
Biogen --- Denali
Biogen --- Ionis
Roche --- AC_Immune
Eli_Lilly --- Academic
Eisai --- Academic
Denali --- Biogen
Prothena --- Roche
The following companies initiated Phase 1 Alzheimer's programs in 2024-2025 with novel mechanisms beyond amyloid targeting:
| Drug |
Company |
Mechanism |
Stage |
| KQ-001 |
Koneqia Therapeutics |
TREM2 modulator |
Phase 1 |
| CC-201 |
Cyclica |
Protein homeostasis |
Phase 1 |
| NP-101 |
Napa Therapeutics |
Mitochondria protectant |
Phase 1 |
| TF-201 |
Trefoil Therapeutics |
Synaptic growth factor |
Phase 1 |
These emerging companies represent diverse technological approaches:
- Brain Access: Koneqia's proprietary BBB platform enables enhanced CNS delivery
- AI-Driven Discovery: Cyclica's MatchMaker™ technology for rapid identification of drug candidates
- Mitochondria-Targeted: Napa Therapeutics' targeted delivery to mitochondrial compartments
- Engineered Proteins: Trefoil's neurotrophic factor engineering platform